The evidence supports individualized treatment selection, biomarker-guided patient assessment, early recognition of toxicity, and multidisciplinary management in cancer immunotherapy, and considers emerging strategies for improving therapeutic precision.
Current challenges in solid tumour treatment are examined through evidence from clinical trials, highlighting key obstacles such as antigen heterogeneity, the immunosuppressive tumour microenvironment, poor cellular trafficking, and treatment-related failures that have informed the development of next-generation CAR co...
A. Justiz-Vaillant, Sachin Soodeen, Rodolfo Arozarena-Fundora et al.· Frontiers in Molecular Medic...· 3 citations
BACKGROUND
With the rapid advancements in oncology, immunology, and molecular biology, immunotherapy has emerged as a cornerstone of anti-tumor treatment, complementing traditional modalities such as surgery, radiotherapy, and chemotherapy. Therapeutic cancer vaccines are a promising immunotherapy strategy that deliver...
Ju-Wei Gao, Yue Sun, Zi-Jing Han et al.· Immunological Investigations· 0 citations
Cancer immunotherapy has emerged as a transformative therapeutic strategy that harnesses the host immune system to recognize and eliminate malignant cells. This review provides a comprehensive overview of current immunotherapeutic approaches, including immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs),...
M. A. Abd El-Hack, Mahmoud Moustafa, M. Kamal et al.· Al-Mustaqbal Journal of Phar...· 0 citations
Overall, TIL therapy constitutes a rapidly evolving and clinically potent treatment modality for melanoma and covers recent advances for improving therapeutic outcomes, including safety optimization, product optimization, next-generation engineered TILs, and predictive biomarkers.
H. Zeng, Wu-Xuan Mei, Chang-Chun Zeng· Current Treatment Options in...· 0 citations
Current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines are discussed.
Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al.· International Journal of Inn...· 0 citations
